<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100420003760N7</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-04-17</date_registration>
      <primary_sponsor>Khoram-Abad University of Medical Sciences</primary_sponsor>
      <public_title>Effect of sublingual soft gel of essential oil of Pistacia atlantica in asthma</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of sublingual soft gel containing Pistacia atlantica oleoresin essential oil on symptomatic and spirometric improvement of patients with moderate to severe asthma compared with standard treatment: A triple-blinded, randomized, placebo-controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-05-24</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>35</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69187</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random allocation of patients into four groups and also using stratified random allocation. In this way, classes are made based on age group (below 40 years and older or equal to 40 years), gender (male and female) and severity (moderate or severe). Within each class, random permutation blocks are used to assign samples to the required groups. To create random sequences,  letters A, B , C  or D(corresponding to the experimental group) will be used as follows.
ABCD: 0-3
ABDC: 4-7
ACBD: 8-11
ACDB:12-15
.
.
DABC
DBAC
DCAB
DCBA: 92-95
Then a corner of the table of random numbers is selected and two-digit numbers are read from top to bottom, and finally, according to the read number, a random sequence of letters A to D is registered in the desired floor. Finally, a random sequence of letters A to D (corresponding to the 4 experimental groups) will be created in each class of all existing classes, and the samples will be assigned to 4 groups based on this random sequence, Blinding description: A random sequence of letters A to D (corresponding to 4 experimental groups) will be created in each class from all the existing classes, and the samples will be assigned to 4 groups based on this random sequence. This study will be triple blind, which means that the pain intensity assessor, the patient and the data analyst are not aware of the type of treatment assigned to the patient. In addition, the decipherer is not a member of the research team, and the sublingual tablets in all groups are completely identical in appearance. Data registration in the statistical software and data analysis is done by the statistical consultant without mentioning the names of the groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Asthma.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group1: The group receiving common treatment and 200 mg sublingual soft gel containing 40 mg of Pistacia atlantica oleoresin  essential oil (Soft gel is made according to the order of the project manager in Kashan Barij Essence Company). Intervention 2: Intervention group2: The group receiving common treatment and 200 mg sublingual soft gel containing 75 mg of Pistacia atlantica oleoresin essential (Soft gel is made according to the order of the project manager in Kashan Barij Essence Company). Intervention 3: Intervention group3: The group receiving common treatment and 200 mg sublingual soft gel containing 150 mg of Pistacia atlantica oleoresin  essential oil (Soft gel is made according to the order of the project manager in Kashan Barij Essence Company). Intervention 4: Control group 1: The group receiving common treatment and 200 mg sublingual soft gel containing 0 mg of Pistacia atlantica oleoresin essential oil (Soft gel is made according to the order of the project manager in Kashan Barij Essence Company).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only part of the data, such as information about the main consequence or similar, can be shared

When:
Start the access period 18 months after printing the results.

To whom:
Data will only be available to researchers working at academic and scientific institutions

Conditions:
The data will only be used to inform the results of the study

Where to obtain:
Lorestan University of Medical Sciences

How to obtain:
Refer to Lorestan University of Medical Sciences, Vice Chancellor of Research and Technology, Research Projects Department, Management of Research Projects Department, 066333120175, Mrs. Sajedi , fax:066333120173 call mrs. zarei 0989167083314

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Marzieh Rashidipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 140, Razi Ave. Pajohandeh Blvd, Herbal Research Center</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6814989468</zip>
        <telephone>+98 66 3312 0172</telephone>
        <email>m_rashidi80@yahoo.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Marzieh Rashidipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 140, Razi Ave. Pajohandeh Blvd, Herbal Research Center</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6814989468</zip>
        <telephone>+98 66 3312 0172</telephone>
        <email>m_rashidi80@yahoo.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients aged 15 years and older who referred to the asthma and allergy specialist's office with a diagnosis of moderate or severe allergic asthma</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having other respiratory diseases except asthma
Pregnant and lactating women
People with a history of drug allergy
Taking anti-leukotriene drugs
People who use supplements or other inhalation and non-inhalation drugs
Having special diseases such as dialysis patients (hemophilia, thalassemia, and MS) and incurable (cystic fibrosis (CF), mucopolysaccharidosis (MPS), spinal muscular atrophy (SMA), metabolic diseases, and autism)
lung cancer</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J45</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Asthma</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group1: The group receiving common treatment and 200 mg sublingual soft gel containing 40 mg of Pistacia atlantica oleoresin  essential oil (Soft gel is made according to the order of the project manager in Kashan Barij Essence Company)</i_keyword>
      <i_keyword>Intervention group2: The group receiving common treatment and 200 mg sublingual soft gel containing 75 mg of Pistacia atlantica oleoresin essential (Soft gel is made according to the order of the project manager in Kashan Barij Essence Company).</i_keyword>
      <i_keyword>Intervention group3: The group receiving common treatment and 200 mg sublingual soft gel containing 150 mg of Pistacia atlantica oleoresin  essential oil (Soft gel is made according to the order of the project manager in Kashan Barij Essence Company)</i_keyword>
      <i_keyword>Control group 1: The group receiving common treatment and 200 mg sublingual soft gel containing 0 mg of Pistacia atlantica oleoresin essential oil (Soft gel is made according to the order of the project manager in Kashan Barij Essence Company).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The times of waking up with an asthma attack during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.</prim_outcome>
      <prim_outcome>The severity of symptoms during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.</prim_outcome>
      <prim_outcome>The amount of restriction in daily activities during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.</prim_outcome>
      <prim_outcome>The severity of breath during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.</prim_outcome>
      <prim_outcome>Wheezing during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.</prim_outcome>
      <prim_outcome>The daily puffs of short-acting inhaled bronchodilators used during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Khoram-Abad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-03-15</approval_date>
        <contact_name>Ethic Committee of Lorestan University of Medical Sciences</contact_name>
        <contact_address>No 20, Anooshirvan Rezaei Square, Lorestan University of Medical Sciences Khorramabad Lorestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
